<DOC>
	<DOCNO>NCT00369785</DOCNO>
	<brief_summary>RATIONALE : Donepezil may help lessen confusion fatigue improve mood quality life patient undergone radiation therapy brain tumor . It yet know whether donepezil effective placebo lessen side effect radiation therapy patient brain tumor . PURPOSE : This randomized phase III trial study donepezil see well work lessen side effect radiation therapy compare placebo patient undergone radiation therapy brain tumor .</brief_summary>
	<brief_title>Donepezil Treating Patients Who Have Undergone Radiation Therapy Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare effect donepezil hydrochloride v placebo , term improve neurocognitive symptom cluster ( i.e. , cognitive impairment , subjective confusion , fatigue ) , patient undergone partial- whole-brain irradiation brain tumor . Secondary - Compare effect regimens mood quality life patient . OUTLINE : This prospective , double-blind , placebo-controlled , randomize , multicenter study . Patients stratify accord prior brain irradiation type ( whole-brain v partial-brain ) study site . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral donepezil hydrochloride twice daily 24 week absence unacceptable toxicity . - Arm II : Patients receive oral placebo twice daily 24 week absence unacceptable toxicity . Patients complete self-reported questionnaire ( quality life , fatigue , subjective confusion , neurocognitive battery , mood ) baseline 12 24 week . PROJECTED ACCRUAL : A total 200 patient accrue study .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>INCLUSION CRITERIA : Adults &gt; 18 year old . Life expectancy least &gt; 30 week . Must receive prior course least 30 Gy fractionate whole partial brain irradiation treatment primary brain tumor metastatic disease brain . Must complete radiation &gt; 6 month prior enrollment radiographic evidence brain disease , stable brain disease define evidence tumor progression 3 month prior enrollment . Patients undergone one treatment single fraction stereotactic radiosurgery ( SRS ) addition whole partial brain irradiation eligible , long SRS complete &gt; 6 month prior registration NED stable disease . Radiation treatment record must available prior radiation treatment ( external beam and/or SRS ) . Patients receive PCI ( prophylactic cranial irradiation ) eligible . Karnofsky Performance Status must &gt; 60 ECOG 02 . Treatment steroid , anticholinergic , antiepileptic , antidepressant , /or sedatives/benzodiazepines acceptable , patient must stable decrease dose time study entry . Patients use narcotic analgesic stable dose and/or prn basis eligible . Patients currently stable dose Methylphenidate Dextramphetamine eligible . For patient brain metastasis , extracranial primary metastatic disease present , must respond local and/or systemic treatment . Must stable 3 month prior enrollment . Must receive chemotherapy time enrollment . Patient must plan therapy , include surgery , brain radiation type , chemotherapy , immunotherapy next 30 week brain extracranial primary metastatic disease . Hormonal therapy patient breast prostate cancer acceptable . Breast patient receive therapy Herceptin allow . Patients must able give informed consent participate study , include sign consent form . Patients must telephone . EXCLUSION CRITERIA : Patients currently take dementia drug , cognitive enhancer , neuroleptic , and/or antiparkinsonian agent . For patient use drug past , must use 2 week prior enrol study . Hypersensitivity donepezil . Patients may currently take Ketoconazole Quindine Arrythmias include bradycardia heartblock Patients receive , GliaSite type brain brachytherapy , ( Gliadel Wafers permit ) convection enhance delivery immunotoxins , and/or investigational modality treatment brain tumor . The effect donepezil develop human fetus recommend therapeutic dose unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . It unknown whether donepezil excrete breast milk , reason woman currently breastfeed eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cognitive/functional effect</keyword>
	<keyword>fatigue</keyword>
	<keyword>psychosocial effect cancer treatment</keyword>
	<keyword>radiation toxicity</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>adult choroid plexus tumor</keyword>
	<keyword>adult craniopharyngioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult anaplastic meningioma</keyword>
	<keyword>meningeal melanocytoma</keyword>
	<keyword>adult meningeal hemangiopericytoma</keyword>
	<keyword>adult grade I meningioma</keyword>
	<keyword>adult grade II meningioma</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult papillary meningioma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult pineoblastoma</keyword>
	<keyword>adult pineocytoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult supratentorial primitive neuroectodermal tumor ( PNET )</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult ependymoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult subependymoma</keyword>
</DOC>